Abstract
All common contributing factors to epilepsy such as trauma, malignancies and infections are accompanied by different levels of central nervous system inflammation that in turn have been associated with the occurrence of seizure. Emerging data from human brain tissue and experimental models of epilepsy support the proposed involvement of inflammation in epilepsy. Key mediators of this process include, among others: interleukin (IL) -1β, IL-6, tumor necrosis factor-α, adhesion molecules and component of complement. Recent advances suggest the involvement of specific inflammatory pathways in the pathogenesis of seizures in patients with pharmacoresistant temporal lobe epilepsy, highlighting the potential for new therapeutic strategies. This review provides an overview of the current knowledge on the relationship between inflammatory mediators and epilepsy. We also describe experimental and clinical evidence of inflammation in epilepsy with special emphasis on clinical aspects once the epileptogenic focus has been resected. Further insight into the complex role of inflammation in epileptogenesis may provide new treatment options.
Keywords: Epilepsy, inflammatory mediators, IL-1β, IL-6, TNF-α, neuroinflammation, temporal lobe epilepsy
Current Pharmaceutical Design
Title:Inflammatory Mediators in Epilepsy
Volume: 19 Issue: 38
Author(s): Lourdes Lorigados Pedre, Lilia M Morales Chacón, Sandra Orozco Suárez, Nancy Pavón Fuentes, Bárbara Estupiñán Díaz, Teresa Serrano Sánchez, Iván García Maeso and Luisa Rocha Arrieta
Affiliation:
Keywords: Epilepsy, inflammatory mediators, IL-1β, IL-6, TNF-α, neuroinflammation, temporal lobe epilepsy
Abstract: All common contributing factors to epilepsy such as trauma, malignancies and infections are accompanied by different levels of central nervous system inflammation that in turn have been associated with the occurrence of seizure. Emerging data from human brain tissue and experimental models of epilepsy support the proposed involvement of inflammation in epilepsy. Key mediators of this process include, among others: interleukin (IL) -1β, IL-6, tumor necrosis factor-α, adhesion molecules and component of complement. Recent advances suggest the involvement of specific inflammatory pathways in the pathogenesis of seizures in patients with pharmacoresistant temporal lobe epilepsy, highlighting the potential for new therapeutic strategies. This review provides an overview of the current knowledge on the relationship between inflammatory mediators and epilepsy. We also describe experimental and clinical evidence of inflammation in epilepsy with special emphasis on clinical aspects once the epileptogenic focus has been resected. Further insight into the complex role of inflammation in epileptogenesis may provide new treatment options.
Export Options
About this article
Cite this article as:
Lorigados Pedre Lourdes, Morales Chacón Lilia M, Orozco Suárez Sandra, Pavón Fuentes Nancy, Estupiñán Díaz Bárbara, Serrano Sánchez Teresa, García Maeso Iván and Rocha Arrieta Luisa, Inflammatory Mediators in Epilepsy, Current Pharmaceutical Design 2013; 19 (38) . https://dx.doi.org/10.2174/1381612811319380009
DOI https://dx.doi.org/10.2174/1381612811319380009 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Programming Apoptosis and Autophagy with Novel Approaches for Diabetes Mellitus
Current Neurovascular Research Protective Effects of the Caffeine Against Neurodegenerative Diseases
Current Medicinal Chemistry Polymer Drug Conjugates: Recent Advancements in Various Diseases
Current Pharmaceutical Design Iptakalim Hydrochloride and Neuronal Protection
Current Neuropharmacology Cyclooxygenase-2 in Synaptic Signaling
Current Pharmaceutical Design Kv7 Channels: Function, Pharmacology and Channel Modulators
Current Topics in Medicinal Chemistry Basic Pharmacology of NMDA Receptors
Current Pharmaceutical Design Natural Medicine:The Genus Angelica
Current Medicinal Chemistry Uridine Function in the Central Nervous System
Current Topics in Medicinal Chemistry Diversity and Variability of the Effects of Nicotine on Different Cortical Regions of the Brain. Therapeutic and Toxicological Implications
Central Nervous System Agents in Medicinal Chemistry Advances in Synthesis and Medicinal Applications of Compounds Derived from Phthalimide
Current Organic Synthesis A Healthy Gut for a Healthy Brain: Preclinical, Clinical and Regulatory Aspects
Current Neuropharmacology Delirium Secondary to Lamotrigine Toxicity
Current Drug Safety Radionuclide Imaging in Drug Development
Current Pharmaceutical Design Signaling Pathways Involved in Antidepressant-Induced Cell Proliferation and Synaptic Plasticity
Current Pharmaceutical Design Autophagy Enhancer Carbamazepine Alleviates Memory Deficits and Cerebral Amyloid-β Pathology in a Mouse Model of Alzheimer's Disease
Current Alzheimer Research The Plastic Phenomenon Underlying the Associative Processes in the Addictive Properties of Diazepam and Other Psychoactive Drugs
Mini-Reviews in Medicinal Chemistry N-Valproyl-L-Tryptophan for CNS-Targeting: Synthesis, Characterization and Efficacy In Vitro Studies of a New Potential Antiepileptic Drug
Medicinal Chemistry Involvement of microRNA-146a in the Inflammatory Response of S tatus Epilepticus Rats
CNS & Neurological Disorders - Drug Targets Agonists and Antagonists of Metabotropic Glutamate Receptors: Anticonvulsants and Antiepileptogenic Agents?
Current Neuropharmacology